14 May 2019
In vitro platform for retinal toxicity assessment and disease modelling
Newcells Biotech Ltd. has developed an in vitro model of the retinal pigmented epithelium, to assess the safety and efficacy of novel ocular compounds. This technology could better predict the outcome in the human eye and reduce the number of animals used to assess the toxicity of ocular drugs. An end-user pharmaceutical company, able to provide access to ocular compounds and data with known in vivo/in vitro toxicity profiles, is sought to validate the model.